A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Namodenoson (Primary)
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 14 Mar 2018 According to a Can Fite media release, Jerusalem and the Rabin Medical Center, Petach Tikva. are the additional two centers of the study.
    • 28 Feb 2018 According to a Can Fite media release, the company expects completion of patient enrollment toward the end of 2018 and data release in the first half of 2019.
    • 23 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top